DEMG: Deltex Medical Group plc - Summary | Jitta

Deltex Medical Group plc

LON:DEMG

Notice
Stock data is unavailable or the company’s delisted.
Price
£0.00
Loss Chance
58.0%
1.59JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (23)
Recent Business Performance (28)
Financial Strength (38)
Return to Shareholders (0)
Competitive Advantage (21)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2023
Operating MarginDeclined
New Share IssuedMore than 50% in 5 years
Cash Conversion CycleMore than 120 days
Key Stats
Jitta Score
Jitta Line
1.59
100.00%
1.59
98.06%
1.59
98.06%
1.25
100.00%
COMPANY DESCRIPTION
Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, and internationally. It offers oesophageal Doppler Probes that is used to guide fluid and drug interventions and haemodynamic monitoring; TrueVue Loops that plots aortic blood flow velocity and aortic blood pressure; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; DoppLink, a patient interface cable that enhances signal processing; and PressureWave, a pulse contour analysis algorithm. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting; and TrueVue monitor. Its products are used in sepsis; abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.